Baystreet Staff - Tuesday, August 28, 2012 Aeterna Zentaris Inc. 09:54 AM EST - Aeterna Zentaris Inc. : announced that a first patient has been recruited for a Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia. Aeterna Zentaris Inc. shares T.AEZ are trading down $0.01 at $0.50.